NCT07105059 - A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 8, 2025

Primary Completion Date

August 8, 2028

Study Completion Date

August 8, 2028

Conditions

Multiple Myeloma

Interventions

DRUG

Teclistamab

After the priming, patients will start Teclistamab step up dosing. Mezigdomide will not be given during the Teclistamab step up. After the priming and step-up, patients will start combination treatment with Teclistamab and Mezigdomide.

DRUG

Mezigdomide

Start with 14 days of Mezigdomide. After the priming and step-up, patients will start combination treatment with Teclistamab and Mezigdomide.

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale